Table 1.
General characteristics of patients
| Parameter | Number (%) |
|---|---|
|
Age (years) |
|
| 18– 24 |
7 (50.0) |
| 25 - 31 |
3 (21,4) |
| 40 - 60 |
4 (28.6) |
|
Sex |
|
| Female |
8 (57.1) |
| Male |
6 (42.9) |
|
Weight (kg) |
|
| 40 - 50 |
5 (35.7) |
| 51 – 60 |
6 (42.9) |
| 61 - 80 |
3 (21.4) |
| Mean ± SD = 56.4 ± 11.2 |
|
|
Height (cm) |
|
| 150 – 160 |
9 (64.3) |
| 161 – 170 |
4 (28.6) |
| 171 – 180 |
1 ( 7.1) |
|
BMI kg/m
2
|
|
| 17.0 – 22.0 |
8 (57.2) |
| 22.1 – 27.0 |
5 (35.7) |
| 27.1 – 32.0 |
1 (7.1) |
| Mean ± SD = 21.9 ± 4.0 |
|
|
Creatinine clearance (mg/mL) |
|
| 80 - 110 |
3 (21.4) |
| 111 - 140 |
6 (42.9) |
| 141 - 170 |
5 (35.7) |
|
Albumin g/dL |
|
| 2.0 – 2.6 |
3 (21.4) |
| 2.7 – 3.3 |
7 (50.0) |
| 3.4 – 4.0 |
4 (28.6) |
| Mean ± SD = 3.0 ± 0.6 |
|
|
Antibiotic given in the previous month? |
|
| Yes |
5 (35.7) |
| No |
9 (64.3) |
|
Malignancy |
|
| Lymphoma |
2 (14.3) |
| Lymphoid leukemia |
9 (64.3) |
| Myeloid leukemia |
3 (21.4) |
|
Number of neutrophils/mm
3
|
|
| Range |
0–2380 |
| Mean ± SD |
208(603.2) |
|
Therapy cycles |
|
| 1 – 2 |
6 (42.9) |
| 3 – 5 |
3(21.4) |
| 6 - 8 |
5 (35.7) |
|
FN-associated chemotherapy |
|
| Hyper-CVAD |
10 (71.4) |
| No Hyper-CVAD | 4 (28.6) |
BMI, body mass index; FN, febrile neutropenia; GFR, glomerular filtration rate.
For Hyper-CVAD chemotherapy, course A comprised cyclophosphamide, vincristine, doxorubicin and dexamethasone, and course B consisted of methotrexate and cytarabine.
Mentioned on page 6.